ArticleMolecular cancer therapeutics2020
Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.
Open access · greenAbstract read
In one paragraph
Article in Molecular cancer therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Bibliometric Analysis of ATAC-Seq and Its Use in Cancer Biology via Nucleic Acid Detection.Frontiers in medicine · 2020Pooled it
- Macrophage Polarization as a Target for Colorectal Cancer Treatment Optimization: A Systematic Review.Cancers · 2026Review
- Spatial and phenotypic plasticity of B cells in remodeling the tumor microenvironment.Journal for immunotherapy of cancer · 2026Review
- Immunometabolic programming of macrophages and tumor-associated macrophages: metabolic pathways shaping polarization, immune regulation, and disease outcomes.Frontiers in immunology · 2026Review
- Myeloid derived suppressor cells in neuroblastoma: mechanisms of immune evasion and therapeutic opportunities.Frontiers in immunology · 2026Review
- Targeting SYK enhances responses to radiotherapy and PD-1 blockade with myeloid immune remodeling in breast cancer.Frontiers in immunology · 2026Article
- Discovery of a "First-in-Class" Selective Multikinase (CDK4/6/9-AURKA/B) Inhibitor, LCI133, for Neuroblastoma.Journal of medicinal chemistry · 2025Article
- PI3K Signaling Pathway Inhibitor Affects Myeloma Cells in a Culture-Dependent Manner.Advanced pharmaceutical bulletin · 2025Article
- Targeting myeloid cells to improve cancer immune therapy.Frontiers in immunology · 2025Review
- Orchestration of Tumor-Associated Macrophages in the Tumor Cell-Macrophage-CD8International journal of biological sciences · 2025Review
- Immunotherapy strategies targeting tumor-associated macrophages and their mechanisms of action in tumor progression.Frontiers in immunology · 2025Review
- Dietary flavonoids may improve insulin resistance: NHANES, network pharmacological analyses and in vitro experiments.PloS one · 2025Article
- New insights into SYK targeting in solid tumors.Trends in pharmacological sciences · 2024Review
- Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2024Article
- SIRPB1 regulates inflammatory factor expression in the glioma microenvironment via SYK: functional and bioinformatics insights.Journal of translational medicine · 2024Article
- A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.Cancer medicine · 2024Article
- Prognostic biomarker SYK and its correlation with immune infiltrates in glioma.Experimental and therapeutic medicine · 2023Article
- Review
- Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.Cancer research · 2023Article
- Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 1 country.
Shweta Joshi *UCSD Department of Pediatrics, University of California, San Diego, San Diego, California. shjoshi@ucsd.edu durden@signalrx.com.
Kevin X LiuUCSD Department of Pediatrics, University of California, San Diego, San Diego, California.ORCID 0000-0003-2071-5137
Muamera ZulcicUCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
Alok R SinghUCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
Dylan SkolaUCSD School of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0002-3655-1643
Christopher K GlassUCSD School of Medicine, University of California, San Diego, San Diego, California.ORCID 0000-0003-4344-3592
P Dominick SandersMoores Cancer Center, Department of Radiation Medicine and Applied Sciences, University of California, San Diego, San Diego, California.
Andrew B SharabiMoores Cancer Center, Department of Radiation Medicine and Applied Sciences, University of California, San Diego, San Diego, California.
Timothy V PhamUCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
Pablo TamayoOffice of Cancer Genomics, University of California, San Diego, San Diego, California.
Daniel ShiangUCSD Department of Pediatrics, University of California, San Diego, San Diego, California.
Huy Q DinhLa Jolla Institute of Allergy and Immunology, La Jolla, California.ORCID 0000-0002-3307-1126
Catherine C HedrickLa Jolla Institute of Allergy and Immunology, La Jolla, California.
Guillermo A MoralesSignalRx Pharmaceuticals, Omaha, Nebraska.
Joseph R GarlichSignalRx Pharmaceuticals, Omaha, Nebraska.
Donald L Durden *UCSD Department of Pediatrics, University of California, San Diego, San Diego, California. shjoshi@ucsd.edu durden@signalrx.com.
University of San Diego · USUniversity of California San Diego · USNebraska Medical Center · USLa Jolla Institute for Immunology · US
Funding
VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9MSupporting Integrative Genomic Analysis Users with GenePatternR01GM074024 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2005 to 2019
$6.6MA Rational Systematic Approach to Find Combinations of Pharmacologic and Immune Therapies that Target Identifiable Oncogenic StatesU01CA217885 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COHEN, EZRA, KAUFMAN, DAN S. · 2017 to 2021
$5.1MStimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6MGenePattern and GenePattern Notebook: Integrative 'Omic Analysis for Cancer ResearchU24CA248457 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2020 to 2024
$4.6MNext-generation Functional Genetic Screening of Un-screenable TraitsR01HG009285 · NHGRI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MALI, PRASHANT, TAMAYO, PABLO · 2017 to 2020
$4.2MSupporting and evolving Gene Set Enrichment Analysis and the Molecular Signatures Database for cancer researchU24CA220341 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P., TAMAYO, PABLO · 2018 to 2022
$3.4MGenePattern Notebooks for Cancer ResearchU24CA194107 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MESIROV, JILL P. · 2015 to 2019
$2.8MDual PI3K/BRD4 Inhibitory Chemotype for Maximum Inhibition of MYC and CancerR01CA215651 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DURDEN, DONALD · 2018 to 2023
$2.3MFunctions of Nonclassical Monocytes in the VasculatureR01CA202987 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI HEDRICK, CATHERINE C · 2016 to 2020
$2.2MMyeloid Syk promotes tumor immunosuppression and inhibits anti-tumor adaptive immunityK22CA229594 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JOSHI, SHWETA · 2020 to 2022
$484kNCI NIH HHS K22 CA229594NCI NIH HHS P30 CA023100NCI NIH HHS R01 CA202987NCI NIH HHS R01 CA215651NCI NIH HHS U01 CA217885NCI NIH HHS U24 CA194107NCI NIH HHS U24 CA220341NCI NIH HHS U24 CA248457NHGRI NIH HHS R01 HG009285NIGMS NIH HHS R01 GM074024RRD VA I01 RX003207RRD VA I21 RX003188
Abstract
Macrophages (MΦ) play a critical role in tumor growth, immunosuppression, and inhibition of adaptive immune responses in cancer. Hence, targeting signaling pathways in MΦs that promote tumor immunosuppression will provide therapeutic benefit. PI3Kγ has been recently established by our group and others as a novel immuno-oncology target. Herein, we report that an MΦ Syk-PI3K axis drives polarization of immunosuppressive MΦs that establish an immunosuppressive tumor microenvironment in
Indexed as
AnimalsApoptosisCarcinoma, Lewis LungCell ProliferationClass Ib Phosphatidylinositol 3-KinaseColonic NeoplasmsCytokinesHumansImmune ToleranceImmunosuppression TherapyMacrophagesMelanoma, ExperimentalMiceMice, Inbred C57BLNF-kappa BPhosphoinositide-3 Kinase InhibitorsClass Ib Phosphatidylinositol 3-KinaseCytokinesNF-kappa BPhosphoinositide-3 Kinase InhibitorsPIK3CG protein, humanSyk KinaseSYK protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.